The Brainstorm Cell Therapeutics team is honored to attend and be a sponsor at the The ALS Association #ALSNexus meeting. We gained valuable insights from the sessions, our interactions with #ALS stakeholders including people living with ALS, their loved ones, advocates, researchers and physicians. We truly are #BetterTogether.
Brainstorm Cell Therapeutics
Biotechnology Research
Kiryat Aryeh, Petach Tikva 5,930 followers
About us
BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Institute for Regenerative Medicine (CIRM) and another grant from the ALS Association. Currently, we are planning a Phase 3b clinical trial of NurOwn® in ALS under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). For more information, visit www.brainstorm-cell.com
- Website
-
http://www.brainstorm-cell.com
External link for Brainstorm Cell Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Kiryat Aryeh, Petach Tikva
- Type
- Public Company
- Founded
- 2004
- Specialties
- stem cell therapy, drug development, neurodegenerative diseases, and ALS
Locations
-
Primary
12 Bazel Street
POB 10019
Kiryat Aryeh, Petach Tikva 49001, IL
-
3 University Plaza Drive
Suite 320
Hackensack, NJ 07601, US
Employees at Brainstorm Cell Therapeutics
-
Antonio Trejo Diaz
-
Haro Hartounian, Ph.D.
CEO | Board Director | C-suite | Biotech Innovator and Entrepreneur | Founder | Life Science l Biotechnology | Cell and Gene Therapy | CDMO |…
-
Antal Pearl-Lendner
General Counsel and VP
-
Mary Kay Turner
Public Affairs, Advocacy, Government Affairs, Communications Executive
Updates
-
Thank you Andrea Pauls Backman, Rick Zwiep, Indu Navar, Layne Oliff and Jennifer DiMartino for participating in Brainstorm Cell Therapeutics' Global #ALSMND Day Campaign. Your commitment to partnership and global collaboration proves we are #BetterTogether. #ALSMNDWithoutBorders #EndALS EverythingALS ALS ONE ALS Action Canada Les Turner ALS Foundation The International Alliance of ALS/MND Associations Centers for Disease Control and Prevention Northeast ALS Consortium (NEALS) ALS Society of Canada Leigh H. Massachusetts General Hospital Dr. Shelena Lalji Team Gleason Foundation Mass General Department of Neurology I AM ALS National Institute of Neurological Disorders and Stroke (NINDS) The National Institutes of Health Foundation for the National Institutes of Health FDA Critical Path Institute (C-Path) UMass Chan Medical School ALS Therapy Development Institute Compassionate Care ALS The ALS Association
-
-
Jennifer DiMartino leads ALS ONE as executive director, serving as a vital link to the #ALS community since its inception in December 2015. ALS ONE is a unique partnership of top #ALS experts from renowned institutions including Mass General Department of Neurology, UMass Chan Medical School, ALS Therapy Development Institute and Compassionate Care ALS. ALS ONE collaborates with Northeast ALS Consortium (NEALS) on the ALS Research Publication Review series bridging the gap between authors of significant #ALS research publications and the #ALSMND community. Through this program, community members can ask questions to fully understand the research, while authors gain direct feedback from the community. ALS ONE provides people living with #ALSMND the resources and community required for their best quality of life. Jen is a passionate connector in the #ALSMND community. #ALSMNDWithoutBorders #BetterTogether #EndALS
-
-
Layne Oliff, a PharmD with decades of biopharma experience and a person living with #ALS, became a prominent advocate in the #ALS community in 2020. Layne contributes extensively through roles with the ALS Problem Solvers, Northeast ALS Consortium (NEALS) PEACe Committee, Mass General Department of Neurology HEALY Platform Patient Advisory Committee, The International Alliance of ALS/MND Associations, I AM ALS and the National Institute of Neurological Disorders and Stroke (NINDS) ALS Strategic Plan steering committee. Currently, Layne serves as the #pALS advisor to the Northeast ALS Consortium (NEALS) Executive Committee and as chairperson of the Accelerating Medicines Partnership (AMP ALS) People with lived experience (PWLE) working group. PWLE are integral to the AMP ALS technical working group alongside staff from The National Institutes of Health, Foundation for the National Institutes of Health, FDA and Critical Path Institute (C-Path). Layne's involvement highlights the value of including those with lived, or as Layne says, "living", experience. PWLE participation is crucial in every part of the #ALSMND community. #ALSMNDWithoutBorders #BetterTogether #EndALS
-
-
Indu Navar, CEO and founder of EverythingALS, pioneers a data-driven and collaborative approach to accelerate #ALS research. Indu is co-hosting "Neurotech Now" joined by Leigh H., MD, PhD, Director of the Center of Neurotechnology and Neurorecovery at Massachusetts General Hospital, Dr. Shelena Lalji, MD, F.A.C.O.G. of ALS Heroes and Team Gleason Foundation at the ALS ONE Research Symposium in November. The aim is to highlight the transformative power of neurotechnology in #ALS. By bringing together researchers, providers and individuals with #ALS globally, EverythingALS promotes open data sharing to spur innovation and advance towards treatments and cures. Indu's commitment to collaboration underscores the belief that the #ALSMND community is #BetterTogether. #ALSMNDWithoutBorders #EndALS
-
-
Since his #ALS diagnosis in August 2022, Rick Zwiep passionately advocates for those living with #ALS. Rick serves on the board of ALS Action Canada. ALS Action Canada, a patient-led non-profit, shares strategic goals and collaborates on research funding with ALS Society of Canada. Together with other dedicated members, Rick helps ensure equitable access to #ALS therapies. Rick built a powerful coalition of people living with #ALS, their families and supporters- all united to #EndALS. Rick raises #ALSMND awareness by highlighting the needs of patients and caregivers. #ALSMNDWithoutBorders #BetterTogether
-
-
Andrea Pauls Backman, founder of ALS Strategy Consulting, spent more than a decade serving as a strategist, chief executive and board member at leading #ALS organizations including Les Turner ALS Foundation, The International Alliance of ALS/MND Associations and The ALS Association. After caring for her mother who was diagnosed with #ALS in 2006, Andrea witnessed firsthand the devastating impact of #ALS. She continues to advance research, education, care and public policy. Andrea advocates for people living with #ALSMND in the United States and globally. Andrea is involved in multiple #ALS projects. She serves as a steering committee member for the new natural history study known as the Access for All in ALS (ALL ALS) consortium. Andrea is facilitating the Centers for Disease Control and Prevention National ALS Registry annual meeting in September. Andrea’s body of work exemplifies how collaboration in the #ALSMND community is essential to #EndALS. #ALSMNDWithoutBorders #BetterTogether
-
-
For Global #ALSMND Day, Brainstorm Cell Therapeutics is amplifying #collaboration within the #ALSMND community by highlighting advocates that are working together across the globe to put an end to #ALSMND. #ALSMNDWithoutBorders #EndALS #BetterTogether
-
-
Exciting news from $BCLI! Haro Hartounian, Ph.D. Hartounian, a seasoned leader with 32+ years in biopharma, specializing in #cell and #gene therapy, joins as COO. His expertise, highlighted by founding and guiding BioCentriq to a $73M acquisition in 2022, strengthens our team for the Registrational Phase 3b ALS trial launch. Welcome aboard, Dr. Hartounian! #EndALS #BetterTogether Read more here: BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer - Jun 20, 2024 https://lnkd.in/gNeTdjsh
-
-
On the fourth annual #LouGehrigDay, we applaud the dedicated #ALS advocates who saw an opportunity to raise awareness for those living with #ALS in front of millions of baseball fans on June 2nd. ⚾️ The original Lou Gehrig Day leadership team, Bryan Wayne, Philip Green, Adam Wilson, and Chuck Haberstroh partnered with Major League Baseball (MLB) to make this incredible day possible. ⚡️ Thanks to the tireless efforts of the #ALS community, Lou Gehrig's legacy and awareness for #ALS are amplified at ballparks nationwide every year. 💫 #LouGehrigDay #MLB4ALS #LG4Day #EndALS #BetterTogether https://lnkd.in/gyPvByxe
-